|
United Arab Emirates Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The United Arab Emirates Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for the United Arab Emirates .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Emirati pharmaceutical and healthcare industry.
Competitive intelligence, Emirati pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Emirati market.
The United Arab Emirates Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s United Arab Emirates Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Emirati pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on the United Arab Emirates to test other views – a key input for successful budgeting and strategic business planning in the Emirati pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Emirati Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in the United Arab Emirates .
- Exploit The Latest Competitive Emirati Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in the United Arab Emirates .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
United Arab Emirates Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| United Arab Emirates Pharmaceuticals And Healthcare Industry SWOT |
| United Arab Emirates Political SWOT |
| United Arab Emirates Economic SWOT |
| United Arab Emirates Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Middle East And Africa Pharmaceutical Business Environment Ratings for Q209 |
| Limits To Potential Returns |
| Risks To Realisation Of Returns |
Chapter - UAE - Market Summary |
| Regulatory Environment |
| Recent Regulatory Developments |
| Pharmaceutical Advertising |
| Intellectual Property Regime |
| Counterfeit Medicines |
| Pricing And Reimbursement Regime |
| Table: Profit Margins For Medicines In The UAE |
| Price Cuts |
| Recent Pricing And Reimbursement Developments |
| Regional Harmonisation |
| Free Trade Agreements |
Chapter - Industry Trends and Developments |
| Epidemiology |
| Healthcare Sector |
| Healthcare Funding |
| Healthcare Sector Reforms |
| Recent Healthcare Sector Developments |
| Hospital Sector Developments |
| Health Insurance |
| Table: DHA Healthcarre System Implementation Timeline |
| Expatriate Worker Insurance |
| Table: National Health Insurance Company – Available Plans |
| Recent Health Insurance Industry Developments |
| Health Tourism |
| Prescribing Practices |
| Domestic Pharmaceutical Sector |
| Foreign Companies |
| Company Developments |
| Pharmaceutical Distribution and Retail |
| Recent Developments in Pharmaceutical Distribution and Retail |
| Research and Development |
| DuBiotech |
| Table: Incentives For Companies To Move To DuBiotech |
| Complementary and Traditional Medicine |
| Medical Devices |
| Recent Developments in the Medical Devices Market |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: UAE - Drug Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: UAE - Health Expenditure Indicators, Historical Data and Forecasts |
| Macroeconomic Scenario |
| Growth Outlook Weakening |
| Table: United Arab Emirates - Economic Activity |
| Prescription Market Forecasts |
| Table: UAE - Prescription Market Indicators, Historical Data and Forecasts (AEDmn unless otherwise stated) |
| Patented Market Forecasts |
| Patented Market Forecasts |
| Table: UAE - Patented Drug Market Indicators, Historical Data and Forecasts |
| Generics Market Forecast |
| Table: UAE- Generics Drug Market Indicators, Historical Data and Forecasts |
| OTC Market Forecast |
| Table: UAE - OTC Drug Market Indicators, Historical Data and Forecasts (AEDmn unless otherwise stated) |
| Pharmaceutical Trade Forecasts |
| Pharmaceutical Trade Forecasts |
| Table: UAE - Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn) |
| Medical Devices |
| Table: UAE - Medical Device Market Indicators, Historical Data and Forecasts (US$mn unless otherwise stated) |
| Other Healthcare Forecasts |
| Table: UAE - Other Healthcare Indicators, Historical Data and Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Profiles |
| Leading Foreign Companies |
| GlaxoSmithKline |
| Pfizer |
| Novartis |
| Johnson & Johnson (J&J) |
| Sanofi-Aventis |
| Abbott Laboratories |
| Merck & Co |
| Indigenous Manufacturers |
| Gulf Pharmaceutical Industries (Julphar) |
| Globalpharma |
| Modern Pharmaceutical Company (MPC) |
| NeoPharma |
Chapter - Country Snapshot: UAE Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2000-2004 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
United Arab Emirates Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The United Arab Emirates (UAE) has retained its pole position in BMI’s Q209 Business Environment Rankings for the 17 key markets within the Middle East and Africa (MEA) region. Globally, the UAE is ranked eighteenth, and is thus comparable to some developed European markets. This high ranking illustrates its capacity to compete with mature markets in terms of the attractiveness of the business environment, especially given UAE’s forecast compound annual growth rate (CAGR) of 9.97% through to 2013. By the end of the forecast period, the market is expected to be valued at AED5.04bn (US$1.37bn) at consumer prices, increasing from AED3.42bn (US$0.85bn) in 2008. Unfavourable fluctuation in the exchange rate of the dirham against the euro already resulted in an increase in drug expenditure during late 2008, which is likely to result in the authorities looking to import cheaper generics and/or to boost local production.
Generally speaking, key drivers of overall market growth will remain the Emirates’ wealthy and urban population, strong preference for branded drugs, rising demand for chronic and long-term diseases treatment and continued investment in health infrastructure. Additionally, the opening of the first pharmacy in a grocery retail store in February 2009 by local pharmacy chain BinSina, on behalf of the global retailer Carrefour, should set the trend for future development of UAE’s over-the-counter (OTC) medicines market, which presently accounts for 17% of the overall market. Over the period 2009-13, OTCs are forcast to post a CAGR of 10.59%, to reach AED912mn (US$248mn) at consumer prices. Indeed, the opening of the hypermarket pharmacy indicates the Ministry of Health’s willingness to encourage improvements of the healthcare sector through innovative solutions.
The government is making concerted efforts to crack down on the trade of counterfeit medicines. Plans unveiled in February 2009 seek to boost the number of customs inspectors and portable drug detectors, especially in the super-busy port of Dubai. By June 2009, unregistered pharmaceutical and healthcare products – as the recent addition of well medical devices and nutritional supplements to the list - will not be permitted to enter or pass through the UAE. In a related development, Tawan Hospital became the first healthcare institution in the Emirates to launch a patient safety programme. The changes also complement the Federal Medical Liability Law, which stipulates that all health professionals – including complementary and alternative medicine (CAM) practitioners – must be insured against medical.
In a worrying development, in January 2009, the UAE dramatically altered laws concerning research and development to prevent human cloning, while also further regulating fertility treatments with regard to implantation and abortion. BMI cautions that, while ethical concerns must be considered, the impact of this law may hinder the development of life sciences in the country, which now includes major global biotechnology players such as Amgen and Genzyne. On the other hand, the government is aiming to rectify the presently unnatural sex distribution, with the population consisting of more than twice as many males as females.
|
United Arab Emirates Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and Turkey |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |